欧州連合 - スロベニア語 - EMA (European Medicines Agency)

pfizer europe ma eeig  - axitinib - karcinom, ledvična celica - proteinska kinaza inhibitorji - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

欧州連合 - スロベニア語 - EMA (European Medicines Agency)

pfizer europe ma eeig - krizotinib - karcinom, pljučni pljuč - antineoplastična sredstva - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

欧州連合 - スロベニア語 - EMA (European Medicines Agency)

pfizer europe ma eeig - dacomitinib monohidrat - karcinom, pljučni pljuč - antineoplastična sredstva - vizimpro, kot monotherapy, je označen za prvo linijo za zdravljenje odraslih bolnikov z lokalno napredno ali metastatskim non small cell lung cancer (nsclc) z epidermalna rastni dejavnik receptorjev (egfr) aktiviranjem mutacije.

欧州連合 - スロベニア語 - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - leukemija, myeloid, akutna - antineoplastična sredstva - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

欧州連合 - スロベニア語 - EMA (European Medicines Agency)

pfizer europe ma eeig - talazoparib - neoplazme dojke - antineoplastična sredstva - talzenna je označen kot monotherapy za zdravljenje odraslih bolnikov z germline brca1/2 mutacije, ki so her2-negativne lokalno napredno ali metastatskega raka dojke. patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. bolniki z hormon receptorjev (hr)-pozitivnega raka dojk, je bilo treba ravnati predhodno endokrine, ki temelji terapije, ali neprimerna za endokrine, ki temelji terapija.

欧州連合 - スロベニア語 - EMA (European Medicines Agency)

pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - imunosupresivi - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

欧州連合 - スロベニア語 - EMA (European Medicines Agency)

pfizer europe ma eeig - bosutinib (kot monohidrat) - leukemija, myeloid - antineoplastic agents, protein kinase inhibitors - bosulif je indiciran za zdravljenje odraslih bolnikov z:novo diagnozo kronična faza (cp) philadelphia kromosom-pozitivno kronične myelogenous levkemijo (ph+ cml). cp, pospešeni fazi (ap), in pišu faza (bp) ph+ cml predhodno zdravljenih z eno ali več tirozin kinaza serotonina(s) [tki(s)] in za koga imatinib, nilotinib in dasatinib ki se ne štejejo za ustrezne možnosti zdravljenja.

欧州連合 - スロベニア語 - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - karcinom, pljučni pljuč - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

欧州連合 - スロベニア語 - EMA (European Medicines Agency)

pfizer europe ma eeig - sirolimus - graft rejection; kidney transplantation - imunosupresivi - zdravilo rapamune je indicirano za profilakso zavrnitve organa pri odraslih bolnikih z majhnim do zmernim imunskim tveganjem, ki prejemajo presaditev ledvic. priporočljivo je, da rapamune uporablja sprva v kombinaciji z ciclosporin microemulsion in kortikosteroidi za 2 do 3 mesece. rapamune lahko nadaljeval, kot vzdrževalna terapija s kortikosteroidi le, če ciclosporin microemulsion lahko postopno opuščeni. rapamune je indiciran za zdravljenje bolnikov z občasno lymphangioleiomyomatosis z zmerno boleznijo pljuč ali upada pljučne funkcije.

欧州連合 - スロベニア語 - EMA (European Medicines Agency)

pfizer europe ma eeig - tafamidis - amiloidoza - druga zdravila na živčnem sistemu - zdravilo vyndaqel je indicirano za zdravljenje transtiretin amiloidoze pri odraslih bolnikih s simptomatsko polinevropatijo stopnje 1, da bi se odložila periferna nevrološka okvara.